Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2012

View Archived Issues

Combination studies of biapenem and RPX-7009 reported

Evolva synthesizes novel topoisomerase inhibitors

Novel anticancer oligopeptides patented by CSIR

Ludwig Institute for Cancer Research discloses novel TbetaR-I blocking antibodies

Kissei Pharmaceutical synthesizes new D2 receptor agonists

BARDA exercises contract option for Emergent's anthrax vaccine candidate

Janssen Biotech patents new antibodies targeting human TF

Cancer Research Technology develops novel TTK inhibitors

Evotec achieves preclinical milestone in drug discovery collaboration with Novartis

ImaginAb and Lundbeck to develop antibodies targeting CNS disorders

New valproic acid prodrugs designed at the University of Florida

TL-118 shows therapeutic potential in mouse model of liver metastases

Cempra reports results from phase I intravenous solithromycin study

Trevena reports initial results from phase IIa study of TRV-027

BioSante Pharmaceuticals and ANI Pharmaceuticals agree to merge

StemCells confirms first transplant of neural stem cells in macular degeneration study

Ferrer completes absorption, tolerability and safety study of novel antibacterial agent

arGEN-X out-licenses anti-IL-6 antibody

GlaxoSmithKline to return rights to GSK-2251052

Chiesi Farmaceutici to market LCP-Tacro in Europe, Turkey and CIS countries

Fibrocell Science raises funds, enters strategic collaboration with Intrexon

Patient dosing begins in phase II trial of Grifols' inhaled alpha1-proteinase inhibitor

Sangart completes enrollment in phase IIb trial of novel ischemic rescue therapy

Revance Therapeutics regains worldwide rights to botulinum toxin products

FDA approves the Dexcom G4 PLATINUM continuous glucose monitoring system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...